How interferon helps cells fight Chlamydia infections
Interferon-inducible cell-intrinsic host defense against Chlamydia trachomatis
Finding out how a natural immune signal called interferon helps human cells block Chlamydia trachomatis infections to reduce long-term problems like pelvic inflammatory disease and infertility.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11248316 on NIH RePORTER |
What this research studies
You can think of this as lab researchers mapping how a key immune protein, interferon-gamma, turns on defenses inside human epithelial cells to stop Chlamydia from growing. They use genome-wide screens in human cells to find which interferon-induced genes are most effective at blocking the bacteria and use mutant libraries of C. trachomatis to find bacterial tricks that overcome those defenses. Most work is done in cell cultures and bacterial models to map the molecular “arms race” between host and pathogen. The findings could point to future drugs, vaccines, or ways to prevent persistent infections.
Who could benefit from this research
Good fit: People with current or recent Chlamydia trachomatis infection or those at high risk who are willing to donate samples for research would be the most relevant candidates for follow-up studies.
Not a fit: Patients seeking immediate treatment or symptom relief are unlikely to benefit directly because this grant supports laboratory-based mechanistic research rather than an interventional clinical trial.
Why it matters
Potential benefit: If successful, the work could reveal new targets for drugs or vaccines that prevent persistent Chlamydia infection and the reproductive complications it can cause.
How similar studies have performed: Previous laboratory studies have shown interferon-gamma can restrict Chlamydia in some settings, but the specific human genes and bacterial countermeasures targeted here remain incompletely defined and are an active area of discovery.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Coers, Joern — Duke University
- Study coordinator: Coers, Joern
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.